Companies › Shandong New Time Pharmaceutical
3 active drug programs in 40 registered trials: 24 Phase 2, 14 Phase 1, 2 Phase 3; Immunology, Oncology, Neurology, Infectious disease; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pomalidomide (F182112) CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM); Relapsed or Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE); Multiple Myeloma … | Dec 2027 |
| Cetirizine Histamine H1 receptor antagonist | HRH1 | Phase 3 | Acute Urticaria | – |
| F520 | – | Phase 2 | Cancer of Unknown Primary Site | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04667663 | Pomalidomide (F182112) | Phase 1 | Multiple Myeloma | Oncology | Apr 2022 |
| NCT02406222 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma | Oncology | Dec 2022 |
| NCT03756896 | Pomalidomide (F182112) | Phase 2 | Plasma Cell Myeloma | Oncology | Jun 2025 |
| NCT06819774 | Cetirizine | Phase 3 | Acute Urticaria | Immunology | Aug 2025 |
| NCT06158412 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma in Relapse | Oncology | Dec 2025 |
| NCT04902443 | Pomalidomide (F182112) | Phase 1 | Viral Associated Malignancies | Oncology | Dec 2026 |
| NCT06342466 | Pomalidomide (F182112) | Phase 2 | Systemic Amyloidosis | Metabolic and endocrine | Dec 2026 |
| NCT06855823 | Pomalidomide (F182112) | Phase 1 | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | Oncology | Dec 2026 |
| NCT04883242 | Pomalidomide (F182112) | Phase 2 | Recurrent Multiple Myeloma | Oncology | Dec 2026 |
| NCT04094961 | Pomalidomide (F182112) | Phase 1 | Multiple Myeloma | Oncology | Jan 2027 |
| NCT04270175 | Pomalidomide (F182112) | Phase 2 | Amyloid | Neurology | Jan 2027 |
| NCT04577755 | Pomalidomide (F182112) | Phase 2 | Skin Kaposi Sarcoma | Oncology | Feb 2027 |
| NCT04508790 | Pomalidomide (F182112) | Phase 2 | Recurrent Plasma Cell Myeloma | Oncology | Feb 2027 |
| NCT06660498 | Pomalidomide (F182112) | Phase 1 | HIV-1 Infection | Infectious disease | Mar 2027 |
| NCT04835129 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma | Oncology | Apr 2027 |
| NCT04802161 | Pomalidomide (F182112) | Phase 2 | Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT03715478 | Pomalidomide (F182112) | Phase 1 | Relapsed and/or Refractory Multiple Myeloma | Oncology | Jun 2027 |
| NCT04124497 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma | Oncology | Jul 2027 |
| NCT07532525 | Pomalidomide (F182112) | Phase 1 | Recurrent B Acute Lymphoblastic Leukemia | Oncology | Aug 2027 |
| NCT04790474 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma in Relapse | Oncology | Sep 2027 |
| NCT03030261 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma in Relapse | Oncology | Sep 2027 |
| NCT04850599 | Pomalidomide (F182112) | Phase 2 | Recurrent Plasma Cell Myeloma | Oncology | Oct 2027 |
| NCT05556798 | Pomalidomide (F182112) | Phase 1 | Multiple Myeloma | Oncology | Oct 2027 |
| NCT05208307 | Pomalidomide (F182112) | Phase 2 | Plasma Cell Myeloma | Oncology | Oct 2027 |
| NCT04764942 | Pomalidomide (F182112) | Phase 1 | Recurrent Multiple Myeloma | Oncology | Dec 2027 |
| NCT04302324 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma | Oncology | Dec 2027 |
| NCT07761429 | F520 | Phase 2 | Cancer of Unknown Primary Site | Oncology | Dec 2027 |
| NCT07829614 | Pomalidomide (F182112) | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Dec 2027 |
| NCT02659930 | Pomalidomide (F182112) | Phase 1 | Kaposi Sarcoma | Oncology | Jan 2028 |
| NCT06879379 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma, Newly Diagnosed | Oncology | Mar 2028 |
| NCT05911321 | Pomalidomide (F182112) | Phase 2 | Multiple Myeloma | Oncology | Mar 2028 |
| NCT07523737 | Pomalidomide (F182112) | Phase 2 | Primary Central Nervous System Lymphoma (PCNSL) | Oncology | Mar 2028 |
| NCT07312188 | Pomalidomide (F182112) | Phase 2 | Relapsed or Refractory Multiple Myeloma | Oncology | May 2028 |
| NCT07312188 | Pomalidomide (F182112) | Phase 2 | Relapsed or Refractory Multiple Myeloma | Oncology | May 2028 |
| NCT07312188 | Pomalidomide (F182112) | Phase 2 | Relapsed or Refractory Multiple Myeloma | Oncology | May 2028 |
| NCT05389423 | Pomalidomide (F182112) | Phase 1 | Diffuse Large Cell Lymphoma | Oncology | Jun 2028 |
| NCT07579234 | Pomalidomide (F182112) | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | Oncology | Jan 2029 |
| NCT07463807 | Pomalidomide (F182112) | Phase 1 | Recurrent Multiple Myeloma | Oncology | Mar 2029 |
| NCT06554561 | Pomalidomide (F182112) | Phase 1 | PCNSL | Oncology | Aug 2029 |
| NCT07749365 | Pomalidomide (F182112) | Phase 2 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Dec 2029 |
Bristol-Myers Squibb Roche Incyte Beijing InnoCare Pharma Tech CellCentric Noucor Health
CellCentric Saol Therapeutics Shanghai Ming Ju Biotechnology Innovent Biopharmaceutical Technology (Hangzhou) Industrial Farmacéutica Cantabria
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.